Cost-Effectiveness Analysis: Lymph Node Transfer vs Lymphovenous Bypass for Breast Cancer-Related Lymphedema.


Journal

Journal of the American College of Surgeons
ISSN: 1879-1190
Titre abrégé: J Am Coll Surg
Pays: United States
ID NLM: 9431305

Informations de publication

Date de publication:
06 2021
Historique:
received: 10 11 2020
revised: 16 02 2021
accepted: 17 02 2021
pubmed: 9 3 2021
medline: 1 10 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

Lymph node transfer (LNT) and lymphovenous bypass (LVB) have been described as 2 major surgical options for patients with breast cancer-related lymphedema (BCRL) who have failed conservative therapy. The objective of our study was to perform a cost-effectiveness analysis comparing LNT and LVB for the treatment of BCRL. Rates of infection, lymph leak, and failure of LNT and LVB were obtained from a previously published meta-analysis. Failure of surgery was defined as the inability to cease compression therapy postoperatively. Procedural costs were calculated from Medicare reimbursement rates. Cost of conservative management of postoperative surgical site infection, lymph leak, and continued decongestive physiotherapy after failed surgery were obtained from literature review. Average utility scores for each health state were calculated using a visual analog scale survey, then converted to quality-adjusted life years (QALYs). A decision tree was constructed, and incremental cost-effectiveness ratio was assessed at $50,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to evaluate the robustness of our findings. LNT was less costly ($22,492 vs $31,927) and more effective (31.82 QALY vs 29.24 QALY) than LVB. One-way (deterministic) sensitivity analysis demonstrated that LNT became cost-ineffective when its failure rate was more than 43.8%. LVB became more cost-effective than LNT when its failure rate was less than 21.4%. Probabilistic sensitivity analysis using Monte-Carlo simulation indicated that even with uncertainty present in the variables analyzed, the majority of simulations (97%) favored LNT as the more cost-effective strategy. LNT is a dominant, cost-effective strategy compared to LVB for the treatment of BCRL.

Sections du résumé

BACKGROUND
Lymph node transfer (LNT) and lymphovenous bypass (LVB) have been described as 2 major surgical options for patients with breast cancer-related lymphedema (BCRL) who have failed conservative therapy. The objective of our study was to perform a cost-effectiveness analysis comparing LNT and LVB for the treatment of BCRL.
STUDY DESIGN
Rates of infection, lymph leak, and failure of LNT and LVB were obtained from a previously published meta-analysis. Failure of surgery was defined as the inability to cease compression therapy postoperatively. Procedural costs were calculated from Medicare reimbursement rates. Cost of conservative management of postoperative surgical site infection, lymph leak, and continued decongestive physiotherapy after failed surgery were obtained from literature review. Average utility scores for each health state were calculated using a visual analog scale survey, then converted to quality-adjusted life years (QALYs). A decision tree was constructed, and incremental cost-effectiveness ratio was assessed at $50,000/QALY. Deterministic and probabilistic sensitivity analyses were performed to evaluate the robustness of our findings.
RESULTS
LNT was less costly ($22,492 vs $31,927) and more effective (31.82 QALY vs 29.24 QALY) than LVB. One-way (deterministic) sensitivity analysis demonstrated that LNT became cost-ineffective when its failure rate was more than 43.8%. LVB became more cost-effective than LNT when its failure rate was less than 21.4%. Probabilistic sensitivity analysis using Monte-Carlo simulation indicated that even with uncertainty present in the variables analyzed, the majority of simulations (97%) favored LNT as the more cost-effective strategy.
CONCLUSIONS
LNT is a dominant, cost-effective strategy compared to LVB for the treatment of BCRL.

Identifiants

pubmed: 33684564
pii: S1072-7515(21)00164-2
doi: 10.1016/j.jamcollsurg.2021.02.013
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

837-845

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Yurie Sekigami (Y)

Department of Surgery, Tufts Medical Center, Boston, MA.

Sydney Char (S)

Tufts University School of Medicine, Boston, MA.

Cate Mullen (C)

Department of Surgery, Tufts Medical Center, Boston, MA.

Kathryn Huber (K)

Department of Radiation Oncology, Tufts Medical Center, Boston, MA.

Yu Cao (Y)

Department of Radiation Oncology, Tufts Medical Center, Boston, MA.

Rachel Buchsbaum (R)

Department of Hematology Oncology, Tufts Medical Center, Boston, MA.

Roger Graham (R)

Department of Surgery, Tufts Medical Center, Boston, MA.

Salvatore Nardello (S)

Department of Surgery, Tufts Medical Center Community Care, Boston, MA.

Dhruv Singhal (D)

Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.

Abhishek Chatterjee (A)

Department of Surgery, Tufts Medical Center, Boston, MA. Electronic address: AChatterjee1@tuftsmedicalcenter.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH